Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy

To determine whether triamcinolone acetonide (TAAC) staining facilitates posterior hyaloid and epiretinal membrane (ERM) removal in patients undergoing pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR). Ten consecutive pseudophakic pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Retina (Philadelphia, Pa.) Pa.), 2003-12, Vol.23 (6), p.771-776
Hauptverfasser: Furino, Claudio, Micelli Ferrari, Tommaso, Boscia, Francesco, Cardascia, Nicola, Recchimurzo, Nicola, Sborgia, Carlo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 776
container_issue 6
container_start_page 771
container_title Retina (Philadelphia, Pa.)
container_volume 23
creator Furino, Claudio
Micelli Ferrari, Tommaso
Boscia, Francesco
Cardascia, Nicola
Recchimurzo, Nicola
Sborgia, Carlo
description To determine whether triamcinolone acetonide (TAAC) staining facilitates posterior hyaloid and epiretinal membrane (ERM) removal in patients undergoing pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR). Ten consecutive pseudophakic patients (10 eyes) underwent PPV for RRD with PVR. After a core PPV, a few drops of a commercially available TAAC aqueous suspension (40 mg/mL) with vehicle were injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloidectomy. Next, 0.1 to 0.2 mL of TAAC was applied on the retinal surface to visualize and peel the ERMs. The tamponading agent was silicone oil (1,300 cs) in eight eyes and perfluropropane (C3F8 14%) in two eyes. The minimal follow-up period in all patients was 4 months. In all patients, intraoperative staining with TAAC consistently improved direct visualization and delineation of the posterior hyaloid and ERMs and facilitated their removal. No adverse reaction related to the use of TAAC was observed immediately postoperatively or 4 months after surgery. Intravitreal TAAC may be an important adjuvant tool in the delineation of posterior hyaloid and ERMs, allowing for a more complete and safer ERM removal in the surgical management of PVR complicating RRD. It is well tolerated with all its vehicle if used at low concentration and rapidly removed during surgery.
doi_str_mv 10.1097/00006982-200312000-00004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71500966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71500966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-908863010f198bd65d1aeaef2a8f5e1ef96bb2d7ee877249291ace9d139e1eb33</originalsourceid><addsrcrecordid>eNpFUE1PwzAMzQHExuAvoJ64FZykbZIjmviSJsFhSNyqtHVEULuUJJvUf0_GBvhgy35-9tMjJKNwQ0GJW0hRKclyBsBpSpDvR8UJmQMTZWqK9xk5D-ETgJZSlmdkRgsBQrJyTl7X3uqhtRvXuw3mOgQbInbZqH3Ixl5vdLaz0WMb3TBlxvls9K63Br2OdocH0HmM6cKo48d0QU6N7gNeHuuCvD3cr5dP-erl8Xl5t8pbLkTMFUhZcaBgqJJNV5Ud1ajRMC1NiRSNqpqGdQJRCsEKxRTVLaqOcpXQhvMFuT7cTXq-thhiPdjQYp8ko9uGWtASQFVVWpSHxda7EDyaevR20H6qKdR7B-tfB-s_B39GRaJeHX9smwG7f-LRPv4NabhwXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71500966</pqid></control><display><type>article</type><title>Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Furino, Claudio ; Micelli Ferrari, Tommaso ; Boscia, Francesco ; Cardascia, Nicola ; Recchimurzo, Nicola ; Sborgia, Carlo</creator><creatorcontrib>Furino, Claudio ; Micelli Ferrari, Tommaso ; Boscia, Francesco ; Cardascia, Nicola ; Recchimurzo, Nicola ; Sborgia, Carlo</creatorcontrib><description>To determine whether triamcinolone acetonide (TAAC) staining facilitates posterior hyaloid and epiretinal membrane (ERM) removal in patients undergoing pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR). Ten consecutive pseudophakic patients (10 eyes) underwent PPV for RRD with PVR. After a core PPV, a few drops of a commercially available TAAC aqueous suspension (40 mg/mL) with vehicle were injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloidectomy. Next, 0.1 to 0.2 mL of TAAC was applied on the retinal surface to visualize and peel the ERMs. The tamponading agent was silicone oil (1,300 cs) in eight eyes and perfluropropane (C3F8 14%) in two eyes. The minimal follow-up period in all patients was 4 months. In all patients, intraoperative staining with TAAC consistently improved direct visualization and delineation of the posterior hyaloid and ERMs and facilitated their removal. No adverse reaction related to the use of TAAC was observed immediately postoperatively or 4 months after surgery. Intravitreal TAAC may be an important adjuvant tool in the delineation of posterior hyaloid and ERMs, allowing for a more complete and safer ERM removal in the surgical management of PVR complicating RRD. It is well tolerated with all its vehicle if used at low concentration and rapidly removed during surgery.</description><identifier>ISSN: 0275-004X</identifier><identifier>DOI: 10.1097/00006982-200312000-00004</identifier><identifier>PMID: 14707825</identifier><language>eng</language><publisher>United States</publisher><subject>Combined Modality Therapy ; Epiretinal Membrane - surgery ; Female ; Fluorocarbons - administration &amp; dosage ; Follow-Up Studies ; Glucocorticoids - therapeutic use ; Humans ; Intraocular Pressure ; Male ; Pseudophakia - complications ; Retinal Detachment - surgery ; Silicone Oils - administration &amp; dosage ; Treatment Outcome ; Triamcinolone Acetonide - therapeutic use ; Visual Acuity ; Vitrectomy - methods ; Vitreoretinopathy, Proliferative - drug therapy ; Vitreoretinopathy, Proliferative - surgery</subject><ispartof>Retina (Philadelphia, Pa.), 2003-12, Vol.23 (6), p.771-776</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-908863010f198bd65d1aeaef2a8f5e1ef96bb2d7ee877249291ace9d139e1eb33</citedby><cites>FETCH-LOGICAL-c377t-908863010f198bd65d1aeaef2a8f5e1ef96bb2d7ee877249291ace9d139e1eb33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14707825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furino, Claudio</creatorcontrib><creatorcontrib>Micelli Ferrari, Tommaso</creatorcontrib><creatorcontrib>Boscia, Francesco</creatorcontrib><creatorcontrib>Cardascia, Nicola</creatorcontrib><creatorcontrib>Recchimurzo, Nicola</creatorcontrib><creatorcontrib>Sborgia, Carlo</creatorcontrib><title>Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy</title><title>Retina (Philadelphia, Pa.)</title><addtitle>Retina</addtitle><description>To determine whether triamcinolone acetonide (TAAC) staining facilitates posterior hyaloid and epiretinal membrane (ERM) removal in patients undergoing pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR). Ten consecutive pseudophakic patients (10 eyes) underwent PPV for RRD with PVR. After a core PPV, a few drops of a commercially available TAAC aqueous suspension (40 mg/mL) with vehicle were injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloidectomy. Next, 0.1 to 0.2 mL of TAAC was applied on the retinal surface to visualize and peel the ERMs. The tamponading agent was silicone oil (1,300 cs) in eight eyes and perfluropropane (C3F8 14%) in two eyes. The minimal follow-up period in all patients was 4 months. In all patients, intraoperative staining with TAAC consistently improved direct visualization and delineation of the posterior hyaloid and ERMs and facilitated their removal. No adverse reaction related to the use of TAAC was observed immediately postoperatively or 4 months after surgery. Intravitreal TAAC may be an important adjuvant tool in the delineation of posterior hyaloid and ERMs, allowing for a more complete and safer ERM removal in the surgical management of PVR complicating RRD. It is well tolerated with all its vehicle if used at low concentration and rapidly removed during surgery.</description><subject>Combined Modality Therapy</subject><subject>Epiretinal Membrane - surgery</subject><subject>Female</subject><subject>Fluorocarbons - administration &amp; dosage</subject><subject>Follow-Up Studies</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Intraocular Pressure</subject><subject>Male</subject><subject>Pseudophakia - complications</subject><subject>Retinal Detachment - surgery</subject><subject>Silicone Oils - administration &amp; dosage</subject><subject>Treatment Outcome</subject><subject>Triamcinolone Acetonide - therapeutic use</subject><subject>Visual Acuity</subject><subject>Vitrectomy - methods</subject><subject>Vitreoretinopathy, Proliferative - drug therapy</subject><subject>Vitreoretinopathy, Proliferative - surgery</subject><issn>0275-004X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUE1PwzAMzQHExuAvoJ64FZykbZIjmviSJsFhSNyqtHVEULuUJJvUf0_GBvhgy35-9tMjJKNwQ0GJW0hRKclyBsBpSpDvR8UJmQMTZWqK9xk5D-ETgJZSlmdkRgsBQrJyTl7X3uqhtRvXuw3mOgQbInbZqH3Ixl5vdLaz0WMb3TBlxvls9K63Br2OdocH0HmM6cKo48d0QU6N7gNeHuuCvD3cr5dP-erl8Xl5t8pbLkTMFUhZcaBgqJJNV5Ud1ajRMC1NiRSNqpqGdQJRCsEKxRTVLaqOcpXQhvMFuT7cTXq-thhiPdjQYp8ko9uGWtASQFVVWpSHxda7EDyaevR20H6qKdR7B-tfB-s_B39GRaJeHX9smwG7f-LRPv4NabhwXQ</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Furino, Claudio</creator><creator>Micelli Ferrari, Tommaso</creator><creator>Boscia, Francesco</creator><creator>Cardascia, Nicola</creator><creator>Recchimurzo, Nicola</creator><creator>Sborgia, Carlo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200312</creationdate><title>Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy</title><author>Furino, Claudio ; Micelli Ferrari, Tommaso ; Boscia, Francesco ; Cardascia, Nicola ; Recchimurzo, Nicola ; Sborgia, Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-908863010f198bd65d1aeaef2a8f5e1ef96bb2d7ee877249291ace9d139e1eb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Combined Modality Therapy</topic><topic>Epiretinal Membrane - surgery</topic><topic>Female</topic><topic>Fluorocarbons - administration &amp; dosage</topic><topic>Follow-Up Studies</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Intraocular Pressure</topic><topic>Male</topic><topic>Pseudophakia - complications</topic><topic>Retinal Detachment - surgery</topic><topic>Silicone Oils - administration &amp; dosage</topic><topic>Treatment Outcome</topic><topic>Triamcinolone Acetonide - therapeutic use</topic><topic>Visual Acuity</topic><topic>Vitrectomy - methods</topic><topic>Vitreoretinopathy, Proliferative - drug therapy</topic><topic>Vitreoretinopathy, Proliferative - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furino, Claudio</creatorcontrib><creatorcontrib>Micelli Ferrari, Tommaso</creatorcontrib><creatorcontrib>Boscia, Francesco</creatorcontrib><creatorcontrib>Cardascia, Nicola</creatorcontrib><creatorcontrib>Recchimurzo, Nicola</creatorcontrib><creatorcontrib>Sborgia, Carlo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Retina (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furino, Claudio</au><au>Micelli Ferrari, Tommaso</au><au>Boscia, Francesco</au><au>Cardascia, Nicola</au><au>Recchimurzo, Nicola</au><au>Sborgia, Carlo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy</atitle><jtitle>Retina (Philadelphia, Pa.)</jtitle><addtitle>Retina</addtitle><date>2003-12</date><risdate>2003</risdate><volume>23</volume><issue>6</issue><spage>771</spage><epage>776</epage><pages>771-776</pages><issn>0275-004X</issn><abstract>To determine whether triamcinolone acetonide (TAAC) staining facilitates posterior hyaloid and epiretinal membrane (ERM) removal in patients undergoing pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) with proliferative vitreoretinopathy (PVR). Ten consecutive pseudophakic patients (10 eyes) underwent PPV for RRD with PVR. After a core PPV, a few drops of a commercially available TAAC aqueous suspension (40 mg/mL) with vehicle were injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloidectomy. Next, 0.1 to 0.2 mL of TAAC was applied on the retinal surface to visualize and peel the ERMs. The tamponading agent was silicone oil (1,300 cs) in eight eyes and perfluropropane (C3F8 14%) in two eyes. The minimal follow-up period in all patients was 4 months. In all patients, intraoperative staining with TAAC consistently improved direct visualization and delineation of the posterior hyaloid and ERMs and facilitated their removal. No adverse reaction related to the use of TAAC was observed immediately postoperatively or 4 months after surgery. Intravitreal TAAC may be an important adjuvant tool in the delineation of posterior hyaloid and ERMs, allowing for a more complete and safer ERM removal in the surgical management of PVR complicating RRD. It is well tolerated with all its vehicle if used at low concentration and rapidly removed during surgery.</abstract><cop>United States</cop><pmid>14707825</pmid><doi>10.1097/00006982-200312000-00004</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0275-004X
ispartof Retina (Philadelphia, Pa.), 2003-12, Vol.23 (6), p.771-776
issn 0275-004X
language eng
recordid cdi_proquest_miscellaneous_71500966
source MEDLINE; Journals@Ovid Complete
subjects Combined Modality Therapy
Epiretinal Membrane - surgery
Female
Fluorocarbons - administration & dosage
Follow-Up Studies
Glucocorticoids - therapeutic use
Humans
Intraocular Pressure
Male
Pseudophakia - complications
Retinal Detachment - surgery
Silicone Oils - administration & dosage
Treatment Outcome
Triamcinolone Acetonide - therapeutic use
Visual Acuity
Vitrectomy - methods
Vitreoretinopathy, Proliferative - drug therapy
Vitreoretinopathy, Proliferative - surgery
title Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T00%3A49%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triamcinolone-assisted%20pars%20plana%20vitrectomy%20for%20proliferative%20vitreoretinopathy&rft.jtitle=Retina%20(Philadelphia,%20Pa.)&rft.au=Furino,%20Claudio&rft.date=2003-12&rft.volume=23&rft.issue=6&rft.spage=771&rft.epage=776&rft.pages=771-776&rft.issn=0275-004X&rft_id=info:doi/10.1097/00006982-200312000-00004&rft_dat=%3Cproquest_cross%3E71500966%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71500966&rft_id=info:pmid/14707825&rfr_iscdi=true